New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2013
11:15 EDTGHDXGenomic Health Oncotype DX recommended in NICE guidance
The U.K.'s National Institute for Health and Clinical Excellence, or NICE, issued draft guidance on four tests used to guide decisions about the use of chemotherapy in people with early breast cancer following consultations on previous drafts and the submission of a confidential access proposal by the manufacturer of Oncotype DX, Genomic Health (GHDX). The draft guidance recommends the use of Oncotype DX in people with oestrogen receptor positive, lymph node negative and human epidermal growth factor receptor 2 negative early breast cancer, who are assessed as being at intermediate risk, to guide chemotherapy decisions where the manufacturer provides it at the price offered through the confidential access proposal. The recommendation for Oncotype DX applies to people assessed as being at intermediate risk of distant recurrence by decision making tools/protocols currently in use in the NHS and where the decision to prescribe chemotherapy remains unclear, NICE said. The draft guidance also highlights that it has not been able to support the routine use of the IHC4, MammaPrint or Mammostrat tests but recommends that they are used in a research setting to collect evidence about potentially important clinical outcomes and to determine the ability of the tests to predict the efficacy of chemotherapy in people with early breast cancer. Reference Link
News For GHDX From The Last 14 Days
Check below for free stories on GHDX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 22, 2014
08:15 EDTGHDXGenomic Health announces two important international milestones
Genomic Health announced two important international milestones including additional reimbursement in Canada and the inclusion of the Oncotype DX breast cancer test in major German clinical guidelines. In Canada, the BC Cancer Agency in British Columbia agreed to fund the Oncotype DX breast cancer test for eligible patients, expanding reimbursement to more than 80% of the country's population. In Germany, updated guidelines from the AGO, or Gynecologic Oncology Working Group, now recommend the Oncotype DX breast cancer test as the only gene expression test to predict chemotherapy benefit in early-stage hormone receptor-positive invasive breast cancer.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use